镰状细胞性贫血检测和筛检市场（按检测类型、产品、最终用户、样本类型和分销管道）—全球预测 2025-2032

预计到 2032 年镰状性贫血检测和筛检市场将成长至 30.3 亿美元，复合年增长率为 13.90%。

为医疗保健领导者提供关于镰状性贫血诊断重点、技术驱动因素、临床工作流程影响和相关人员决策的策略入门指南

镰状细胞性贫血检测处于诊断创新、公共卫生重点和不断发展的临床实践的交汇点。以下介绍概述了当代检测现状、推动对准确及时诊断需求的临床需求，以及影响医疗机构技术应用的策略性考量。本文重点介绍了检测设计、样本处理和数据解读的进步如何重塑诊断工作流程，同时回应了日益增长的人口健康筛检需求意识。

临床医生和实验室负责人面临着提高诊断准确性、缩短週转时间和控製成本的双重压力。因此，检测方法的选择越来越依赖于在分析性能与适用性、监管透明度和供应链弹性之间取得平衡。同时，研究机构和生物技术开发者正在挑战分子和高解析度技术的极限，以实现更早的检测和更详细的基因表征。因此，相关人员必须应对快速变化的生态系统，在这个生态系统中，临床效用、扩充性以及与电子医疗系统的整合决定了长期价值。

本介绍为深入探讨变革性市场变化、关税影响、细分市场细微差别、区域动态、企业行为和可行建议奠定了基础。它强调了将技术创新与切实可行的实施策略相结合的重要性，以改善患者治疗效果并优化不同医疗环境中的资源利用率。

技术融合、护理路径重新设计、劳动力技能转变以及伙伴关係主导的交付如何重塑镰状细胞性贫血的检测和筛检实践

由于技术日趋成熟、诊断途径的重构以及对人群筛检的日益重视，镰状细胞性贫血的检测领域正在发生重大变化。新型分子检测和次世代定序方法补充了传统的基于蛋白质的方法，使临床医生能够将基因型分析与表型评估相结合，从而获得更全面的诊断结果。同时，侧流免疫检测和自动化分析仪的创新正在降低分散式检查的门槛，扩大门诊病人和社区环境中的检测可及性。

在营运方面，实验室正在采用更模组化的工作流程，并将用于变异分离的高效液相层析与分子确认检测相结合，从而在提高诊断确定性的同时简化了通量。数位化结果管理与电子医疗系统的互通性的整合正在加速临床决策支持，使护理团队能够更快地根据阳性观察采取行动。同时，支付方和公共卫生计画正在重新调整检测途径，以强调新生儿和产前筛检、早期疗育以及与护理的联繫，从而产生了对可大规模部署的标准化、高品质检测的需求。

最后，竞争格局正在转向设备製造商、耗材供应商和服务供应商合作提供端到端解决方案。这些策略伙伴关係关係旨在减少部署摩擦，增强客户支持，并扩展培训资源，促进先进诊断方法在医疗机构的广泛应用。

评估 2025 年美国关税政策变化对镰状细胞检测供应链的多方面营运、供应链和策略影响

美国宣布的2025年关税调整对镰状性贫血检测所用诊断设备、试剂和辅助耗材的整个供应链产生了复杂的下游影响，实验室和经销商正在重新审视其供应商关係，以降低进口成本上升的风险。因此，采购团队正在多元化其供应商组合，寻求更近的生产地点，并协商长期合同，以稳定投入的可用性和价格的可预测性。

在产品层面，关税正在影响製造商对生产地点和全球分销结构的决策。一些公司正在加快对国内或区域製造能力的投资，以缓解关税相关的脆弱性，而其他公司则正在优化材料清单和包装，以降低关税分类风险。这些策略性因应措施，加上对供应链透明度和库存缓衝的日益重视，共同影响前置作业时间、营运成本需求和产品上市时间。

在临床方面，虽然检测的基本绩效特征将保持不变，但随着相关人员努力协调采购并控製成本，引入新平台和耗材的时间表可能会延长。政策制定者和行业协会正在积极与监管机构和贸易官员沟通，以澄清关税解释，并倡导对基本医疗用品实施豁免和分阶段引入。同时，实验室和卫生系统正在采取缓解策略，例如整合订单、利用集团采购组织以及扩展本地校准和维护能力，以在不断变化的贸易条件下保持服务的连续性。

细粒度細項分析揭示了测试模式、产品系列、最终用户资料、样本模式和管道策略如何相互作用以影响诊断采用

了解市场细分可以揭示检测技术、产品系列、最终用户、样本类型和分销通路如何影响其应用和服务。依检测类型划分，包括高效液相层析、免疫测量和分子检测法，包括用于免疫测量酵素结合免疫吸附检测法(ELSA) 和侧流分析法，以及用于分子检测的次世代定序仪和聚合酵素链锁反应平台。每种检测方法在分析深度、通量和易用性方面都有各自的优缺点，这会影响它们在医疗保健环境中的部署位置和方式。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 在分散的医疗环境中整合新生儿护理照护现场新生儿筛检工具
• 采用高通量基因组定序工作流程对新生儿进行早期带因者检测
• 引进人工智慧模式识别软体，在筛检测试中区分镰状细胞特征
• 实施基于 CRISPR 的分子检测，以准确检测镰状镰状细胞基因变异
• 使用智慧型手机比色法扩大农村地区镰状细胞疾病筛检的覆盖范围
• 扩大撒哈拉以南非洲地区卫生系统的强制性新生儿镰状细胞疾病筛检项目
• 开发整合电子健康记录系统，将筛检结果与病患照护路径连结起来
• 新生儿筛检阳性后远距遗传咨询远端医疗平台的构建
• 透过政府机构和私人实验室的合作，支持社区的镰状细胞筛检工作

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

镰状性贫血检测与筛检市场（依检测类型）

• 高效液相层析
• 免疫检测
  • 酵素结合免疫吸附试验
  • 横向流动
• 分子检测
  • 次世代定序
  • 聚合酵素链锁反应

镰状细胞性贫血检测和筛检市场（按产品）

• 耗材
  • 套件
  • 试剂
• 装置
  • 高效液相层析系统
  • 免疫检测分析仪
  • 分子诊断平台
• 服务
  • 维护和支援
  • 培训和咨询

镰状性贫血检测与筛检市场（依最终用户）

• 诊断实验室
  • 医院实验室
  • 独立实验室
• 医院和诊所
  • 私人诊所
  • 公立医院
• 研究机构
  • 学术机构
  • 政府研究中心

镰状性贫血检测与筛检市场（依样本类型）

• 血液样本
  • 微血管血
  • 静脉血
• 唾液样本
  • 收集套件
  • 直接收集

镰状细胞性贫血检测与筛检市场（依通路）

• 直接地
  • 公司自有销售队伍
• 间接地
  • 经销商
  • 网路零售

镰状细胞性贫血检测与筛检市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

镰状细胞性贫血检测与筛检市场（依群体）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

镰状性贫血检测和筛检市场（按国家/地区）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Becton, Dickinson and Company
  • Siemens Healthineers AG
  • DiaSorin SpA
  • PerkinElmer, Inc.
  • Ortho Clinical Diagnostics, Inc.
  • QIAGEN NV

The Sickle Cell Anemia Testing & Screening Market is projected to grow by USD 3.03 billion at a CAGR of 13.90% by 2032.

A strategic primer on sickle cell anemia diagnostic priorities, technological drivers, clinical workflow implications, and stakeholder decision imperatives for healthcare leaders

Sickle cell anemia testing is at the intersection of diagnostic innovation, public health priorities, and evolving clinical practice. The introduction below frames the contemporary testing landscape, the clinical imperatives driving demand for accurate and timely diagnosis, and the strategic considerations shaping technology adoption across healthcare settings. It emphasizes how advances in assay design, sample handling, and data interpretation are reconfiguring diagnostic workflows while responding to increasing awareness of population health screening needs.

Clinicians and laboratory leaders face simultaneous pressures to improve diagnostic accuracy, shorten turnaround times, and manage costs. As a result, test selection increasingly balances analytical performance with operational compatibility, regulatory clarity, and supply chain resilience. In parallel, research institutions and biotechnology developers are pushing the envelope on molecular and high-resolution techniques to enable earlier detection and deeper genetic characterization. Consequently, stakeholders must navigate a rapidly changing ecosystem where clinical utility, scalability, and integration with electronic health systems determine long-term value.

This introduction sets the stage for a deeper exploration of transformative market shifts, tariff impacts, segmentation nuances, regional dynamics, corporate behaviors, and actionable recommendations. It underscores the importance of aligning technical innovation with pragmatic implementation strategies to improve patient outcomes and optimize resource use across diverse care environments.

How technological convergence, care pathway redesign, workforce skill shifts, and partnership-driven offerings are reshaping sickle cell anemia testing and screening practices

The landscape of sickle cell anemia testing is undergoing transformative shifts driven by technological maturation, diagnostic pathway reengineering, and a stronger focus on population-level screening. Emerging molecular assays and next-generation sequencing approaches are complementing traditional protein-based methods, enabling clinicians to combine genotypic insight with phenotypic assessment for more comprehensive diagnostic clarity. Concurrently, innovations in lateral flow immunoassays and automated analyzers are lowering barriers to decentralized testing, expanding access in outpatient and community settings.

Operationally, laboratories are adopting more modular workflows that integrate high-performance liquid chromatography for variant separation with molecular confirmatory testing, which improves diagnostic certainty while streamlining throughput. The integration of digital result management and interoperability with electronic health systems is accelerating clinical decision support, enabling care teams to act sooner on positive findings. At the same time, payers and public health programs are recalibrating testing pathways to emphasize newborn and prenatal screening, early intervention, and linkage to care, creating demand for standardized, high-quality tests that can be deployed at scale.

Finally, the competitive landscape is shifting toward collaborations between instrument manufacturers, consumable suppliers, and service providers to deliver end-to-end solutions. These strategic partnerships aim to reduce implementation friction, enhance customer support, and expand training resources, thereby facilitating broader adoption of advanced diagnostic modalities across varied care settings.

Assessing the multifaceted operational, supply chain, and strategic repercussions of United States tariff policy changes in 2025 on sickle cell testing supply chains

United States tariff adjustments announced for 2025 have introduced a complex set of downstream effects across the supply chain for diagnostic instruments, reagents, and ancillary consumables used in sickle cell anemia testing. The immediate operational impact centers on procurement cycles and supplier selection, as laboratories and distributors reassess vendor relationships to mitigate exposure to increased import costs. As a consequence, procurement teams are diversifying supplier portfolios, seeking nearer-shore manufacturing, and negotiating longer-term contracts to stabilize input availability and price predictability.

At the product level, tariffs are influencing manufacturers' decisions about where to locate production and how to structure global distribution. Some firms are accelerating investments in domestic or regional manufacturing capacity to reduce tariff-related vulnerability, while others are optimizing bill-of-materials and packaging to lessen tariff classification risk. These strategic responses are coupled with increased emphasis on supply chain transparency and inventory buffering, which collectively affect lead times, working capital requirements, and the cadence of product launches.

Clinically, while the fundamental performance characteristics of tests remain unchanged, implementation timelines for new platforms and consumables can be extended as stakeholders navigate procurement adjustments and cost-containment initiatives. Policymakers and industry associations are actively engaging with regulators and trade officials to clarify tariff interpretation and to advocate for exemptions or phased implementation for essential medical goods. In parallel, laboratories and health systems are adopting mitigation tactics such as consolidating orders, leveraging group purchasing organizations, and expanding local calibration and maintenance capabilities to preserve service continuity amid evolving trade conditions.

Granular segmentation analysis revealing how test modalities, product portfolios, end user profiles, sample modalities, and channel strategies interact to influence diagnostic adoption

Understanding market segmentation provides clarity on how testing technologies, product portfolios, end users, sample types, and distribution pathways collectively shape adoption and service delivery. Based on test type, the landscape is composed of high performance liquid chromatography, immunoassay, and molecular assay approaches, with immunoassay options spanning enzyme linked immunosorbent assay and lateral flow formats, and molecular assay choices including next generation sequencing and polymerase chain reaction platforms. Each test family delivers distinct trade-offs between analytical depth, throughput, and ease of use, which influence where and how they are implemented across care settings.

Based on product, offerings are differentiated as consumables, instruments, and services. Consumables encompass kits and reagents that are the recurring elements of testing workflows; instruments include HPLC systems, immunoassay analyzers, and molecular diagnostic platforms that determine throughput and integration complexity; and services cover maintenance and support as well as training and consultancy necessary to ensure technical competence and operational continuity. The balance among these product pillars informs cost structures and supplier value propositions.

Based on end user, deployment spans diagnostic laboratories, hospitals and clinics, and research institutes. Diagnostic laboratories further bifurcate into hospital based labs and independent labs, hospitals and clinics divide into private clinics and public hospitals, and research institutes include academic institutions and government research centers. Based on sample type, testing workflows rely on blood samples and saliva samples, with blood subdivided into capillary blood and venous blood and saliva broken into collection kits and direct collection methods, each affecting sample integrity and collection logistics. Finally, based on distribution channel, products reach users via direct and indirect channels, where direct engagement is typified by a company owned sales force and indirect routes employ distributors and online retail, creating different service expectations and commercialization dynamics.

Regional dynamics and differentiated adoption pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence diagnostic deployment and strategic planning

Regional dynamics shape adoption patterns, regulatory pathways, and investment priorities for sickle cell anemia testing in meaningful ways. In the Americas, established clinical networks and newborn screening infrastructure support widespread use of established assay platforms, while innovation is concentrated around integrating molecular confirmation into routine workflows and expanding community-based screening programs. Health systems in this region also place higher emphasis on reimbursement alignment and value demonstration, which affects how novel technologies are introduced into clinical practice.

In Europe, the Middle East and Africa, heterogeneous regulatory frameworks and variable healthcare infrastructure produce a mosaic of opportunities and challenges. Western Europe tends to prioritize centralized high-complexity testing and regulatory rigor, while parts of the Middle East and Africa are rapidly expanding decentralized screening capacity and point-of-care solutions to address gaps in access. Cross-border collaborations, donor-funded initiatives, and capacity-building programs are playing pivotal roles in accelerating diagnostic availability in underserved areas throughout this combined region.

Asia-Pacific presents dynamic growth in local manufacturing, digital health integration, and public health programs that emphasize early detection. Several markets within the region are investing in both high-throughput laboratory automation and low-cost point-of-care tests to serve diverse geographies. Across all regions, variations in procurement pathways, regulatory timelines, and training resources influence adoption speed and the types of solutions that gain traction, reinforcing the need for regionally nuanced commercialization and implementation strategies.

How diagnostic manufacturers, consumable suppliers, and service providers are aligning innovation, partnerships, and operational support to strengthen the sickle cell testing value chain

Corporate behavior within the sickle cell testing ecosystem reflects a mix of platform innovation, lifecycle management, and ecosystem partnerships. Leading instrument manufacturers continue to enhance automation, throughput, and user ergonomics while extending service networks to reduce downtime and total cost of ownership for clinical laboratories. Consumable suppliers are emphasizing kit stability, streamlined workflows, and compatibility across instrument platforms to expand addressable markets and reinforce customer stickiness.

Specialized biotechnology and molecular diagnostics firms are prioritizing assay specificity and turnaround time improvements, with many pursuing collaborative arrangements with larger firms to scale distribution and regulatory access. Service providers and consultancy firms are differentiating through training, validation support, and custom assay development offerings that help clinical and research customers accelerate implementation and meet local regulatory requirements. Moreover, strategic alliances between diagnostic companies and academic or clinical centers are fostering translational pipelines that move promising assay concepts into validated, real-world use cases.

Across the competitive landscape, companies are also focusing on supply chain resilience, software-enabled services, and bundled solutions that combine instruments, consumables, and knowledge services. These integrated approaches are designed to reduce friction during procurement and implementation while providing measurable operational benefits to laboratories, hospitals, and public health programs.

Practical strategic priorities for diagnostic firms to strengthen resilience, accelerate adoption, and align innovation with clinical and operational demands in sickle cell testing

Industry leaders must adopt pragmatic, forward-looking strategies to navigate evolving clinical expectations, regulatory shifts, and supply chain uncertainties. First, prioritizing platform interoperability and modular test architectures will enable laboratories to adopt incremental upgrades without disruptive capital investments. Second, investing in regional manufacturing and diversified supplier networks can reduce exposure to trade policy changes and improve supply continuity for instruments and consumables. These measures should be complemented by robust supplier qualification processes and flexible contracting arrangements to manage procurement risk.

Third, expanding service offerings beyond traditional maintenance to include comprehensive training, validation support, and digital tools for quality assurance will differentiate providers and lower adoption barriers for end users. Fourth, engaging proactively with regulators and public health bodies to align test validation frameworks and reimbursement pathways will accelerate clinical integration and promote equitable access. Finally, companies should cultivate collaborative relationships with clinical centers and research institutions to co-develop clinically relevant assays and to generate real-world evidence that demonstrates clinical utility and operational feasibility.

By implementing these strategic priorities, industry participants can enhance resilience, accelerate responsible innovation, and deliver diagnostic solutions that meet the dual imperatives of clinical effectiveness and operational practicality across diverse healthcare environments.

Transparent multi-source research approach combining expert interviews, literature synthesis, and segmentation analysis to produce validated diagnostic market insights

The research methodology underpinning this report synthesizes multiple qualitative and quantitative sources to ensure robust, reproducible insights. Primary research includes structured interviews with laboratory directors, clinical specialists, procurement managers, and diagnostic product leaders to capture firsthand perspectives on workflow preferences, adoption barriers, and technology requirements. Secondary research leverages peer-reviewed clinical literature, regulatory guidance documents, and technology white papers to contextualize assay performance characteristics, sample handling considerations, and validation approaches.

The analytical framework integrates segmentation mapping across test types, product categories, end users, sample modalities, and channels to identify patterns of technology deployment and service needs. Regional analysis draws on policy reviews and implementation case studies to highlight regulatory and infrastructure drivers. Triangulation techniques were applied to reconcile differing inputs and to surface consensus viewpoints, while sensitivity checks were used to test the robustness of thematic findings.

Throughout the research process, emphasis was placed on methodological transparency, expert validation, and the avoidance of proprietary source dependency, ensuring that conclusions reflect a balanced synthesis of clinical, operational, and commercial perspectives relevant to stakeholders across the diagnostic ecosystem.

Synthesis of diagnostic innovation and operational resilience imperatives that together determine successful implementation and impact in sickle cell screening and testing

In conclusion, the sickle cell anemia testing landscape is characterized by simultaneous technological advancement and pragmatic implementation challenges. Molecular and high-resolution techniques are expanding the diagnostic toolkit, while improved immunoassay formats and automated systems are enhancing accessibility and throughput. At the same time, evolving trade policies, supply chain dynamics, and regional heterogeneity require adaptive commercialization and procurement strategies to ensure consistent access to high-quality testing.

For stakeholders across clinical, laboratory, and policy domains, success will depend on aligning innovation with operational realities: selecting technologies that offer the right balance of analytical performance, ease of use, and integration capability; investing in workforce training and service support; and pursuing supply chain diversification to manage external shocks. Collaborative models that link manufacturers, clinical centers, and public health programs offer a pragmatic route to scale validated solutions and to accelerate equitable access to testing across diverse care settings.

Ultimately, a cohesive approach that couples technological excellence with resilient operational design will be essential to translate diagnostic advances into measurable improvements in patient identification, clinical management, and population health outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of point-of-care neonatal screening tools in decentralized healthcare settings
• 5.2. Adoption of high-throughput genomic sequencing workflows for early carrier detection in newborns
• 5.3. Deployment of AI-driven pattern recognition software to differentiate sickle cell trait in screening assays
• 5.4. Implementation of CRISPR-based molecular assays for precise detection of rare sickle cell gene variants
• 5.5. Utilization of smartphone-enabled colorimetric assays to expand rural sickle cell screening access
• 5.6. Expansion of mandatory newborn sickle cell screening programs across sub-Saharan African health systems
• 5.7. Development of integrated electronic health record systems linking screening results to patient care pathways
• 5.8. Establishment of telemedicine platforms for remote genetic counseling following positive newborn screening results
• 5.9. Collaboration between governmental agencies and private laboratories to subsidize community sickle cell screening initiatives
• 5.10. Introduction of multiplex immunoassay panels to enhance diagnostic throughput and reduce turnaround time in sickle cell testing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sickle Cell Anemia Testing & Screening Market, by Test Type

• 8.1. High Performance Liquid Chromatography
• 8.2. Immunoassay
  • 8.2.1. Enzyme Linked Immunosorbent Assay
  • 8.2.2. Lateral Flow
• 8.3. Molecular Assay
  • 8.3.1. Next Generation Sequencing
  • 8.3.2. Polymerase Chain Reaction

9. Sickle Cell Anemia Testing & Screening Market, by Product

• 9.1. Consumables
  • 9.1.1. Kits
  • 9.1.2. Reagents
• 9.2. Instruments
  • 9.2.1. HPLC Systems
  • 9.2.2. Immunoassay Analyzers
  • 9.2.3. Molecular Diagnostic Platforms
• 9.3. Services
  • 9.3.1. Maintenance & Support
  • 9.3.2. Training & Consultancy

10. Sickle Cell Anemia Testing & Screening Market, by End User

• 10.1. Diagnostic Laboratories
  • 10.1.1. Hospital Based Labs
  • 10.1.2. Independent Labs
• 10.2. Hospitals & Clinics
  • 10.2.1. Private Clinics
  • 10.2.2. Public Hospitals
• 10.3. Research Institutes
  • 10.3.1. Academic Institutions
  • 10.3.2. Government Research Centers

11. Sickle Cell Anemia Testing & Screening Market, by Sample Type

• 11.1. Blood Sample
  • 11.1.1. Capillary Blood
  • 11.1.2. Venous Blood
• 11.2. Saliva Sample
  • 11.2.1. Collection Kits
  • 11.2.2. Direct Collection

12. Sickle Cell Anemia Testing & Screening Market, by Distribution Channel

• 12.1. Direct
  • 12.1.1. Company Owned Sales Force
• 12.2. Indirect
  • 12.2.1. Distributors
  • 12.2.2. Online Retail

13. Sickle Cell Anemia Testing & Screening Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Sickle Cell Anemia Testing & Screening Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Sickle Cell Anemia Testing & Screening Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. F. Hoffmann-La Roche Ltd
  • 16.3.2. Abbott Laboratories
  • 16.3.3. Thermo Fisher Scientific Inc.
  • 16.3.4. Bio-Rad Laboratories, Inc.
  • 16.3.5. Becton, Dickinson and Company
  • 16.3.6. Siemens Healthineers AG
  • 16.3.7. DiaSorin S.p.A.
  • 16.3.8. PerkinElmer, Inc.
  • 16.3.9. Ortho Clinical Diagnostics, Inc.
  • 16.3.10. QIAGEN N.V.

LIST OF FIGURES

• FIGURE 1. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 263. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 264. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 265. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 266. AM